← board
RGC
distress 4/10 · elevated risk$5.91-1%today-89% from 52w high
regencellbioscience.com10 employeesFounded 2014Causeway Bay, Hong KongDrug Manufacturers - Specialty & Generic
Revenue
pre-revenue
Liquidity
$5M
Runway
1.6 yrs
Shares 1y
+4845%
Price & events
-80.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
+23.5%
1W
-46.7%
1M
-79.1%
3M
-81.2%
6M
-60.1%
1Y
+1399.9%
2Y
+2352.4%
5Y
+2037.0%
All
Overview
- Market Cap
- $2.92B
- Volume
- 23.10K
- 52 Week Range
- $4.78 – $52.88
- Total Shares
- 494.49M
- Float Shares
- 56.28M
- Short %
- 1.37%
- % Held by Insiders
- 88.38%
- % Held by Institutions
- 0.14%
- RVOL
- 0.05x
- Beta
- 1.83
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.